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Individualised	  pelvic	  floor	  muscle	  training	  in	  women	  3 
with	  pelvic	  organ	  prolapse:	  a	  multicentre	  randomised	  4 
controlled	  trial	  5 	  6 Abstract	  7 Background	  Pelvic	  organ	  prolapse	  is	  common	  and	  is	  strongly	  associated	  with	  childbirth	  and	  increasing	  age.	  Women	  8 with	  prolapse	  are	  often	  advised	  to	  do	  pelvic	  floor	  muscle	  exercises,	  but	  supporting	  evidence	  is	  limited.	  Our	  aim	  was	  to	  9 establish	  if	  one-­‐to-­‐one	  individualised	  pelvic	  floor	  muscle	  training	  (PFMT)	  is	  effective	  in	  reducing	  prolapse	  symptoms.	  10 	  11 Methods	   A	   parallel-­‐group	   multicentre	   randomised	   controlled	   trial	   (ISRCTN35911035)	   in	   female	   outpatients	   with	  12 newly-­‐diagnosed,	  symptomatic	  stage	  I,	  II	  or	  III	  prolapse,	  comparing	  five	  PFMT	  appointments	  over	  16	  weeks	  (n=225)	  13 versus	  a	  lifestyle	  advice	  leaflet	  (n=222).	  Treatment	  allocation	  was	  by	  remote	  computer	  allocation	  using	  minimisation.	  14 Our	   primary	   endpoint	   was	   participants’	   self-­‐report	   of	   prolapse	   symptoms	   at	   12	   months.	   Group	   assignment	   was	  15 masked	  from	  outcome	  assessors.	  We	  compared	  outcomes	  between	  trial	  groups	  in	  an	  intention-­‐to-­‐treat	  analysis.	  The	  16 cost	  of	  PFMT	  and	  savings	  on	  subsequent	  treatments	  were	  calculated	  to	  estimate	  cost-­‐effectiveness.	  17 	  18 Findings	  Compared	   to	   the	   control	   group,	   the	   intervention	  group	   reported	   fewer	  prolapse	   symptoms	  at	  12	  months	  19 (mean	  difference	  between	  groups	  in	  change	  score	  1.52,	  95%	  CI	  [0.46,	  2.59],	  p=0.0053);	  reported	  their	  prolapse	  to	  be	  20 “better”	  more	  often	  (57.2%	  versus	  44.7%,	  difference	  12.6%,	  95%	  CI	  [1.1%,	  24.1%],	  p=0.0336);	  and	  had	  an	  increased	  21 but	  non-­‐significant	  odds	  of	  having	  less	  severe	  stage	  of	  prolapse	  at	  their	  6-­‐month	  clinical	  examination,	  (OR	  1.47,	  95%	  22 CI	  [0.97,	  2.27],	  p=0.07).	  The	  control	  group	  had	  a	  greater	  uptake	  of	  other	  prolapse	  treatment	  (49.6%	  versus	  24.1%,	  23 
difference 25.5%, 95%	   CI	   [14.5%,	   36.0%],	   p<0.0001).	   Findings	   were	   robust	   to	   missing	   data.	   The	   net	   cost	   of	   the	  24 intervention	  was	  £131.61	  per	  woman	  and	  the	  cost	  per	  one-­‐point	  reduction	  in	  the	  symptom	  score	  was	  £86.59,	  95%	  CI	  25 [£50.81,	  £286.11].	  	  26 	  27 Interpretation	   One-­‐to-­‐one	   PFMT	   for	   prolapse	   is	   effective	   in	   improving	   prolapse	   symptoms.	   Longer-­‐term	   benefits	  28 should	  be	  investigated,	  as	  should	  the	  effects	  in	  specific	  subgroups.	  29 	  	  30 Funding	  Chief	  Scientist	  Office,	  Scottish	  Government	  Health	  Directorates;	  New	  Zealand	  Lottery	  Board;	  National	  Health	  31 and	  Medical	  Research	  Council	  Australia	  (Grant	  number	  508925).	  	  32 Word	  count	  308	  33 
34 
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Introduction	  3 
Pelvic organ prolapse is a common female condition, with 40% of women over the age of 50 years having some 4 
degree of prolapse on examination.1 Approximately 11% of all women undergo surgery for urinary incontinence or 5 
prolapse during their lifetime, and 7% for prolapse alone.2 In England around 29,000 prolapse repairs were performed 6 
in 2010/20113 at a cost of around £60m, and surgery numbers are likely to increase substantially as the population 7 
ages.4 Increasing age and parity, and family history of prolapse have been reported as the main risk factors for 8 
prolapse, although factors such as obesity, heavy lifting and constipation may also play a role.5 One study reported a 9 
total population-attributable risk for prolapse of 46% associated with having prolapse symptoms during pregnancy, a 10 
mother with prolapse, and undertaking heavy physical work.6 Prolapse is characterised by symptomatic descent of the 11 
vaginal walls, apex or vault from the normal anatomical position.7 Women with prolapse may present with vaginal, 12 
bladder, bowel, back, abdominal and sexual symptoms. The condition can affect daily activities and quality of life. 13 
Current treatment options include surgery and conservative management, the latter being considered if the prolapse is 14 
less severe or the woman is a poor candidate for surgery. Conservative interventions include: physical interventions 15 
which aim to improve pelvic floor muscle function and support via pelvic floor muscle training (PFMT); mechanical 16 
interventions which aim to support the prolapse (e.g. use of vaginal pessaries); and lifestyle interventions which seek 17 
to avoid exacerbation of the prolapse by decreasing intra-abdominal pressure (e.g. weight loss, avoiding heavy 18 
lifting). 19 
 20 
Many physiotherapists who specialise in women’s health offer women with prolapse individualised PFMT.8 The aim 21 
of PFMT is to improve pelvic floor muscle function (strength, endurance and coordination) and ultimately increase 22 
the structural support for the pelvic organs. There is evidence that PFMT is effective in the treatment of urinary 23 
incontinence9 but the evidence for PFMT in the management of prolapse is less clear. The Cochrane systematic 24 
review updated in 201110 identified four trials (including two pilot trials) comparing PFMT with control, two of which 25 
were at significant risk of bias. Symptoms, although measured differently in different studies, were improved in the 26 
short-term in three trials, and pooled data on severity from two trials indicated an improvement post-treatment in 27 
prolapse stage due to PFMT. The review concluded that reliable evidence relating to effectiveness and cost-28 
effectiveness of PFMT for symptomatic prolapse in the medium and long term is needed. 29 
 30 
We report findings of the Pelvic Organ Prolapse PhysiotherapY (POPPY) trial which compared an individualised 31 
PFMT programme compatible with UK NHS practice (five one-to-one appointments over 16 weeks), with a control 32 
group allocated to a prolapse lifestyle advice leaflet and no PFMT.	  Our hypothesis was that, in women with stage I to 33 
III prolapse of any type, one-to-one pelvic floor muscle training, as compared to a lifestyle advice leaflet, would 34 
reduce the symptoms of prolapse and the need for further prolapse treatment, and that it would be a cost-effective 35 
treatment for prolapse. 36 	  37 Methods	  38 
Participants	  39 
Between September 2007 and February 2010 we identified new attendees at outpatient gynaecology clinics presenting 40 
with symptomatic prolapse in 25 centres (23 UK; 1 Dunedin, New Zealand; 1 Sydney, Australia). Centres were a mix 41 
of university teaching hospitals and district general hospitals, all offering similar specialist pelvic floor physiotherapy 42 
services. Women were asked to take part if stage I, II or III prolapse of any type (anterior, posterior, apical, or a 43 
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combination) was confirmed by their gynaecologist on vaginal examination using the Pelvic Organ Prolapse 3 
Quantification (POP-Q) measurement system,11 and if prolapse was their main presenting complaint.  4 
 5 
We excluded women if they had had previous prolapse treatment including surgery, if they were pregnant or less than 6 
six months post-natal, or if they were unable to comply with the intervention (i.e. if they were not able to attend the 7 
clinic for appointments with the physiotherapist). Women who, on examination, were deemed to need treatment for 8 
vaginal atrophy were eligible after completing a course of local oestrogens.  9 
 10 
The trial methods were based on our pilot trial findings.12 Women gave signed informed consent to being randomised 11 
and to long-term follow-up. Our trial was carried out in accordance with the Declaration of Helsinki. It was approved 12 
by: Scotland A Research Ethics Committee, Edinburgh, Scotland; Lower South Regional Ethics Committee, Ministry 13 
of Health, Dunedin; Human Research Ethics Committees of The University of Melbourne, Victoria, Australia and St 14 
George Hospital, Kogarah, New South Wales, Australia. It was overseen by an independent Trial Steering Committee 15 
(TSC) and a separate, independent Data Monitoring Committee (DMC). 16 	  17 
Procedures	  18 
Women allocated to the intervention were invited to attend five one-to-one PFMT appointments over 16 weeks (at 19 
weeks 0, 2, 6, 11 and 16) with a women’s health physiotherapist. The intervention duration of 16 weeks was chosen 20 
on the basis of both muscle physiology (15 weeks specific muscle training is required to gain muscle hypertrophy13) 21 
and UK clinical guidelines for the management of urinary incontinence recommend PFMT for “at least 3 months”.14 22 
Appointment frequency was based on current practice within the UK NHS; first appointments close together to allow 23 
reinforcement of correct exercise technique and understanding of all advice given, later appointments becoming 24 
further apart to encourage independent home exercise.  25 
 26 
At the first appointment an explanation of types of prolapse, pelvic floor muscle anatomy and function were given 27 
using diagrams and a model pelvis. Internal pelvic floor muscle assessment to correct exercise technique and assess 28 
muscles (using the PERFECT Scheme)15 was completed. An individualised home exercise programme was prescribed 29 
based on examination findings. Women were encouraged to progress exercises, aiming for ten times ten second 30 
maximal holds and up to fifty fast contractions, three times per day and to record all exercises in a diary. Women were 31 
also taught how to pre-contract the pelvic floor muscles against increases in intra-abdominal pressure (“the knack”) 32 
and encouraged to use this technique daily. The home exercise programme was modified at each appointment as 33 
indicated by examination findings and diary recordings. The use of electromyography biofeedback, pressure 34 
biofeedback and electrical stimulation were not permitted. Trial physiotherapists attended training prior to their 35 
involvement in intervention delivery within the trial. No additional training was given to physiotherapists during 36 
intervention delivery. 37 
 38 
Participants received a lifestyle advice leaflet that gave advice about weight loss, constipation, avoidance of heavy 39 
lifting, coughing and high impact exercise: control women received this by post, whilst intervention group women 40 
received it at their first appointment. The leaflet contained no information about pelvic floor muscle exercises or 41 
techniques. Women attended a review appointment with their gynaecologist at six months post-trial entry, at which 42 
time they could be referred for further prolapse treatment if desired. 43 	  44 
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We used postal questionnaires to collect data at the time of trial entry (baseline), and at 6 and 12 months after trial 3 
entry. Our primary clinical endpoint was prolapse symptoms at 12 months as measured by the Pelvic Organ Prolapse 4 
Symptom Score (POP-SS),16 a validated, patient-completed instrument with seven items, relating to frequency of 5 
prolapse symptoms over the previous four weeks, each scored from 0 (never) to 4 (all of the time) (total score 0 to 28). 6 
Secondary outcomes included: women’s perceived change in prolapse since the start of the study (same, better, 7 
worse); quality of life measured as interference of prolapse symptoms with everyday life (scored 0 ‘not at all’ to 10 ‘a 8 
great deal’); number of days with prolapse symptoms in the previous four weeks; uptake of further prolapse treatment 9 
(surgery, ring pessary, referral to physiotherapy, referral to dietician, oestrogen cream/tablets or HRT); impact of 10 
incontinence (International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form - ICIQ UI 11 
SF – scored 0 to 21, higher values indicating greater severity)17; bowel symptoms (early short form version of ICIQ 12 
bowel symptom questionnaire provided by the developers); sexual symptoms (Pelvic Organ Prolapse/Urinary 13 
Incontinence Sexual Questionnaire, PISQ-12)18; general health (SF-12)19; use of health services in primary and 14 
secondary care; and frequency of the practice of pelvic floor muscle exercises in last 4 weeks (a few times only, once 15 
a week, a few times a week, once a day, a few times a day, and contractions per day: <5, 5–10, 11–20, 21–30, 31–60, 16 
>60). Intervention adherence was measured in terms of attendance at appointments and the amount of exercise women 17 
recorded in their daily exercise diary. In addition, the physiotherapists delivering the intervention collected data at 18 
each appointment about women’s adherence to the prescribed exercise. 19 
 20 
Assessment of prolapse type and stage by the gynaecologist in clinic was carried out in all women before group 21 
allocation and at the 6-month review appointment using the POP-Q system.11 Formal POP-Q training was given at 22 
each trial centre initiation visit. This included: a verbal explanation of POP-Q system; observation of the American 23 
Urogynecological Society POP-Q training DVD; information on standardising conditions for POP-Q examination 24 
(e.g. examination position, bladder emptying, equipment use); use of the recording form and a question and answer 25 
session. Each centre was provided with a copy of the DVD and the publication describing the POP-Q.11 Centres were 26 
encouraged to carry out further in-house training, and additional centre visits were offered if necessary. 27 
 28 
 29 
Group	  allocation	  and	  masking 30 
Women were allocated to groups using the remote-computer determined randomisation application at the Centre for 31 
Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, UK. Treatment allocation 32 
used minimisation to balance group sizes on key prognostic factors at baseline. These were centre, stage of prolapse 33 
(I, II or III), and the woman’s motivation for prolapse surgery (not considering surgery/considering surgery). The 34 
latter is potentially an important factor influencing how adherent women will be to PFMT. The university-based trial 35 
coordinator accessed the web-based application and then informed the woman, and the physiotherapist as necessary, 36 
of the allocated group. The intervention could not be masked from women or treating physiotherapists. Outcome 37 
assessment was by participant-completed questionnaires, thus avoiding assessor bias: data entry was carried out 38 
blinded to group allocation. The gynaecologist undertaking the POP-Q assessment at 6 months was blinded to 39 
women’s trial group until after the examination.  40 
 41 
Sample	  size	  42 
We estimated a difference between groups in mean POP-SS of 2.5 as our effect size, based on the pilot trial.12 With 43 
253 women per group the trial had 80% power at the 5% significance level to detect a different of 2.5 points in the 44 
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primary outcome measure, assuming a common standard deviation (SD) of 8 points.20 This calculation allowed for 3 
10% loss to follow-up overall, and 15% of the control group receiving all of the benefit of PFMT by undertaking 4 
exercises under their own initiative. 5 
 6 
Statistical	  analysis	  7 
We tabulated descriptive statistics, reporting baseline demographics and clinical characteristics with means and SDs, 8 
or median and inter-quartile range (IQR) as appropriate. We used intention-to-treat analyses to compare the primary 9 
outcome at 12 months by fitting a linear mixed effects model to change from baseline in POP-SS at 6 and 12 months, 10 
with a random intercept for subject within centre and a random slope for time within subject, and adjusted for baseline 11 
POP-SS score and the minimisation variables. Such models implicitly adjust the model estimates where there are 12 
missing data, assumed them to be missing at random, according to observed values.21 Women who had observations at 13 
baseline and at least one follow-up time-point were included in the model. The difference between the intervention 14 
and control groups in estimated mean change from baseline was presented for 6 and 12 months with 95% confidence 15 
intervals and p-values. We also assessed the assumption of missing at random and corresponding impact of missing 16 
responses on the primary outcome using multiple imputation.22 Model assumptions were checked using residual plots 17 
and found to hold. 18 
 19 
POP-Q stage was compared between groups in an ordinal regression model with 6 month POP-Q stage as the 20 
dependent variable, and baseline POP-Q stage and minimisation variables as covariates. The pooled odds ratio from 21 
the ordinal model was calculated with a 95% confidence interval and p-value. Stage II prolapse was subdivided 22 
depending on whether the prolapse was above the hymen, or at the hymen or below. Change in POP-Q stage between 23 
baseline and six months was also presented. Other secondary outcomes were compared between groups using the 24 
Mann-Whitney (M-W) test for continuous and ordinal variables and the chi-squared or Fisher’s exact test for 25 
categorical variables. 26 
 27 
Through planned subgroup analyses we explored the effect on the primary outcome of prolapse stage and type, age 28 
and motivation for surgery, using stricter levels of statistical significance (two-sided p<0·01). 29 
 30 
Analyses were conducted according to a pre-specified Statistical Analysis Plan using the R programming package23 31 
and the mi package in R24 for post-hoc multiple imputation analysis. The analyst was independent of the research team 32 
and was blinded to group allocation until after the main analysis had been undertaken. 33 
 34 
Economic	  analysis 35 
Our economic assessment was a within-trial analysis at 12 months after recruitment taking an NHS cost perspective. 36 
Direct health-service costs were used to generate the total cost for each participant. Based on the number of trial 37 
physiotherapy appointments attended, we estimated the amount of physiotherapy time which was involved in the 38 
delivery of the intervention and the associated costs of clinic space. All women were asked in follow-up 39 
questionnaires about their use of health services (general practitioner, practice nurse consultations) and any further 40 
prolapse treatment they had received. Costs were attributed to these items using UK data from: Personal Social 41 
Services Research Unit, Unit Costs of Health and Social Care; Scottish Health Service Costs; British National 42 
Formulary; and C&G Medicare Limited.25–28 The costs were balanced against changes in the primary clinical 43 
outcome. We assumed that where we observed a difference between the trial groups in rates of subsequent treatments 44 
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such as surgery at the end of the trial follow-up period, these represented savings. Sensitivity analyses were performed 3 
to assess the possible impacts of varying the intervention effect size and the uptake of subsequent prolapse treatment. 4 
 5 
This trial is registered with Current Controlled Trials, number ISRCTN35911035. 6 
 7 
Role	  of	  the	  funding	  source	  8 
The funders of the study had no role in trial design, data collection, data analysis, data interpretation, or writing of the 9 
report. GM, JN, SB, AE, SH and AW had access to trial data. All authors agreed to submit for publication. 10 	  11 Results	  12 
We approached 2093 women attending outpatient gynaecology clinics of whom 603 were eligible and 447 (74%) 13 
consented to take part in the trial (Figure 1). Follow-up rates for questionnaires were 85% (381/447) at 6 months and 14 
66% (295/447) at 12 months; 77% (365/477) attended for 6-month review. Non-responders at 12 months were 15 
significantly younger and had a higher BMI than responders. There was no evidence of differential dropout between 16 
the trial groups. The mean age of participants was 56.8 years (SD 11.5); the median number of births per woman was 17 
2 (range 0 to 7); 412/445 (92.6%) of women had had at least one vaginal birth, 28/447 (6.3%) had had at least one 18 
caesarean section, 118/445 (26.5%) had had at least one forceps delivery, and 9/447 (2.0%) had had a vacuum 19 
extraction. Women were on average in the overweight category (mean BMI 27, SD 5.1). The most common 20 
presentation was combined anterior, posterior and upper compartment prolapse (202/445 (45.4%)), followed by 21 
combined anterior and posterior (108/445 (24.3%)). Most women (338/447 (75.6%)) had stage II prolapse (95/447 22 
(21.3%) above the hymen, 243/447 (54.4%) at or below the hymen). Median duration of prolapse symptoms was 12 23 
months (IQR 6 to 24). As expected for a trial of this size, the trial groups were well-balanced on clinical and 24 
demographic factors at baseline (Table 1).  25 
 26 
Intervention adherence  27 
Of the women allocated to the intervention group, 80% (178/222) attended 4 or 5 out of the possible 5 physiotherapy 28 
appointments over the 16 week intervention period (Table 2).	  Adherence to the prescribed number of sets of exercise 29 
or greater between appointments was achieved by just under three quarters of women. Women in the intervention 30 
group were more likely than those in the control group, although not significantly so, to report performance of pelvic 31 
floor exercises in the last four weeks at 12-month follow-up (115/147 (78%) versus 95/138 (69%); risk difference 32 
9.4%, 95% CI [-0.8%, 19.6%], p=0.07; risk ratio 1.13, 95% CI [0.96, 1.34], p=0.15). 33 
 34 
Adverse effects 35 
Eight adverse events (6 vaginal symptoms, 1 back pain, 1 abdominal pain) and one unexpected serious adverse event 36 
(skiing injury), defined as affecting normal everyday activities, were reported by participants; all were from women in 37 
the intervention group. None of these were judged to be related to the intervention or to trial participation. 38 
 39 
Prolapse outcomes 40 
Women in the intervention group reported more improvement in prolapse symptoms (a significantly greater reduction 41 
in POP-SS) compared to the control group both at 6 months (difference between groups in change from baseline 2.84, 42 
95% CI [2.05, 3.63], p<0.0001) and at 12 months (1.52, 95% CI [0.46, 2.59], p=0.0053) (Table 3). Combining the 43 
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results of refitting the model to five imputations of the missing POP-SS scores gave very similar estimates of the 3 
differences between the groups (6 months: 2.79, 95% CI [1.91, 3.67], 12 months: 1.66, 95% CI [0.74, 2.58]). 4 
 5 
The most commonly reported symptom at baseline was “a feeling of something coming down” (around 90% in both 6 
groups, Table 1); this persisted at 6 and 12 months (Table 3). All POP-SS symptoms were significantly less common 7 
in the intervention group at 6 months, and for “discomfort worse when standing” and “lower abdominal heaviness” 8 
this was true at 12 months also (Table 3). Women in the intervention group were also less likely to report having 9 
prolapse symptoms in the last 4 weeks both at 6 and 12 months (Table 3). 10 
 11 
When asked “how do you feel your prolapse is now compared to the start of the study?”, intervention women were 12 
significantly more likely than controls to report their prolapse was “better”, both at 6 months (98/187 (52%) versus 13 
32/189 (17%), M-W p<0.0001) and 12 months (83/145 (57%) versus 63/141 (45%), M-W p=0.0125) (Table 3).  14 
 15 
After adjusting for baseline POP-Q stage, centre and whether the woman was motivated to have surgery, the odds of a 16 
less severe prolapse stage at six months was greater in the intervention group although this was not significant (OR 17 
1.47, 95% CI [0.97, 2.27], p=0.07). A greater proportion of women in the intervention group had an improvement in 18 
their prolapse stage by 6 months (45/168 (26.8%) versus 33/171 (19.3%), Table 5) but this was not significant (risk 19 
difference 7.5%, 95% CI [-1.4%, 16.4%], p=0.10; risk ratio 1.39 [95% CI 0.94 to 2.06], p=0.10). 20 
 21 
Effect of prolapse on quality of life and other clinical outcomes 22 
Women were asked to report how much prolapse interfered with dimensions of their quality of life and about other 23 
symptoms (Table 4). At 6 months the intervention group scores were significantly lower (better) in all aspects of daily 24 
life, and sexual, bladder and bowel function (except for faecal incontinence), but this was not evident at 12 months 25 
(Table 4). 26 
 27 
 28 
Further prolapse treatment 29 
We asked women what further prolapse treatment they had received. By 12 months, significantly more control women 30 
(71/143 (49.6%)) reported they had received further treatment compared to the intervention women (35/145 (24.1%)) 31 
(risk difference 25.5%, 95% CI [14.5%, 36.0%], p<0.0001; risk ratio 2.1, 95% CI [1.5, 2.9], p<0.0001). There was a 32 
similar uptake of surgery, pessary and other non-trial treatments in the trial groups by 12 months, but significantly 33 
more control women had received a physiotherapy referral for PFMT (Table 5).  34 
 35 
Subgroups 36 
The treatment effect at 12 months was consistent for all subgroups pre-specified in the analysis plan. That is, there 37 
were no significant interactions between trial group and any of the subgroup terms in the model: prolapse stage (I to 38 
III) (p=0.38), prolapse type (most descended part anterior/posterior/upper) (p=0.61), age (under 50/50 years or over) 39 
(p=0.29); and motivation for surgery (keen/wants to avoid) (p=0.89).  40 
 41 
Costs and benefits 42 
The cost of the physiotherapy intervention was £170.24 based on an hourly cost of a Band 6 physiotherapist of 43 
£30.67.25 Trial physiotherapists reported initial appointments took 80 minutes (60 minutes face-to-face plus 20 44 
10 
 
minutes of administration); follow-up appointments (maximum of 4) took 40 minutes. For overheads such as the cost 3 
of the examination room, a figure of £16 per appointment was used.26 On average women attended for 4.2 sessions out 4 
of the possible 5 therefore we applied an 84% uptake.rate. 5 
 6 
Based on the questionnaire responses regarding further treatment received, and published cost estimates of the various 7 
treatment courses (surgery £1,044;26 pessary £229.45;27,28 referral for physiotherapy £170.24, oestrogen/HRT 8 
£195.5127), the difference between the groups in mean cost of subsequent treatment was £38.63 (95% CI [-£41.95, 9 
£126.41], p=0.34). The mean cost per woman in the control group was £306.86 (95% CI [£250.74, £368.29]), and 10 
intervention group £268.23 (95% CI [£210.35, £333.59]). Overall the net cost of the intervention per woman was 11 
£170.24 - £38.63 = £131.61.  12 
 13 
This cost is set against a significant difference between groups in the primary clinical outcome measure. The net cost 14 
per one-point improvement in POP-SS was £131.61/1.52, or £86.59. When we consider the 95% confidence interval 15 
around the difference in change in POP-SS from baseline (0.46 to 2.59), the cost per point improvement on POP-SS 16 
ranges from £51.81 to £286.11. When we consider the 95% confidence interval around the net costs (£170.24-£126.41 17 
to £170.24+£41.95) the cost per point improvement on POP-SS ranges from £28.84 to £139.60. 18 Discussion	  19 
We found a greater reduction in prolapse symptoms in the PFMT group at 12 months when compared to the control 20 
group. The difference was both statistically significant, and of a magnitude that would be important to women, as it 21 
exceeded the minimally important change for the POP-SS.29 This finding was supported by a higher uptake of 22 
supplementary treatments (principally PFMT) in the control group after 6 months indicating residual need; a lower 23 
prevalence of each individual prolapse symptom, as well as in bladder, bowel and sexual symptoms, and better quality 24 
of life in the intervention group after 6 months of PFMT. Women in the intervention group were also more likely to 25 
say their prolapse was “better” at both 6 and 12 months. While more women in the intervention group demonstrated 26 
improvement in prolapse stage, this was not significantly different between the groups. Subgroup analyses indicated 27 
that these findings of effectiveness held regardless of the woman’s prolapse stage or type, her age or her attitude 28 
towards having surgery. 29 
 30 
Since there was a high degree of uptake of some form of PFMT in the control group before the primary outcome 31 
assessment at 12 months, and no evidence of differential use of other non-PFMT interventions, it seems plausible that 32 
the intention-to-treat treatment effect estimate is an underestimate of the benefit associated with PFMT at 12 months. 33 
We are confident therefore that the significant treatment effects reported represent real effects that are of importance 34 
to women and clinicians. 35 
 36 
By 12 months a greater proportion of control women than intervention women had received further prolapse treatment 37 
(49% versus 23%), predominantly PFMT between 6 and 12 months: a quarter of the control group women sought a 38 
referral to physiotherapy, giving them access to PFMT, indicating residual need for treatment. However, similar 39 
proportions of women in both groups had undergone prolapse repair surgery by 12 months (11% intervention and 40 
10% control), or received a pessary.  41 
 42 
The observation that at 12 months the control group were as likely to be exercising as the intervention group may be 43 
explained partly by the uptake of physiotherapy in the control group. It is encouraging that almost 80% of intervention 44 
11 
 
women were still exercising at 12 months, as long-term adherence is an important consideration for the effectiveness 3 
of this intervention. 4 
 5 
The net cost of the intervention was £131.61 per woman. The main determinant of the cost is of providing the 6 
intervention. The main area of uncertainty is the longer-term impact of PFMT on the need for subsequent treatments 7 
such as pessaries, physiotherapy and surgery: our results are based on the trial follow-up period and we cannot 8 
exclude the possibility that treatments have been delayed rather than avoided. The sensitivity analyses show the 9 
plausible ranges around our results, however there are reasons for believing that the higher costs are unlikely, notably 10 
that the expenditure on the intervention is a one-off so all the costs have been incurred and it is plausible that the 11 
benefits in terms of reduced symptoms and treatments avoided will continue to accrue over time.  12 
 13 
Assuming that intervention women gained 10% on their quality of life for a year as a result of the intervention, the 14 
cost per quality adjusted life year (QALY) gained is around £16,000. This level of cost per QALY is commonly 15 
accepted as worthwhile by organisations such as the National Institute for Health and Clinical Excellence in the UK.  16 
 17 
The main strengths of the trial were its size, rigour and pragmatic design, with the intervention being relevant to UK 18 
NHS practice, and potentially to other similar health systems worldwide, and the outcomes being woman-centred. 19 
Participants’ compliance with trial processes and the intervention were generally high. Unlike other trials in this area, 20 
our main focus was the prolapse symptoms which led the women to seek treatment, and which we used to measure 21 
treatment success.  22 
 23 
In terms of limitations, we achieved 88% of our target sample size of 506, and experienced a lower questionnaire 24 
response rate at 12 months (66%) than expected, despite postal and telephone reminders. However, as the observed 25 
SD of the POP-SS was smaller than originally assumed, we nevertheless had sufficient power to identify important 26 
differences. There was no evidence of differential dropout as the response rate was similar in both trial groups, and 27 
results were also found to be robust to missing data. Not all women had a prolapse assessment at 6 months; therefore 28 
there was also attrition in the POP-Q responses (75% intervention, 77% control). This may have contributed to the 29 
non-significant POP-Q finding. There was significant crossover of control women to the intervention due to their 30 
uptake of PFMT after 6 months, and this makes interpretation of the findings more challenging. A further limitation is 31 
the short follow-up period of 12 months: due to natural fluctuation in prolapse symptoms and the effect of different 32 
treatment modalities, clinical and cost differences between the groups might be expected to change with time. Women 33 
included in this trial were treatment-naïve, presenting for treatment for the first time. However, PFMT may also be 34 
effective in enhancing surgical or pessary treatment, or for use after surgical failure, or shortly after childbirth and 35 
these situations need further research. In the economic analysis we did not estimate QALYs gained since we found in 36 
our pilot work that the SF-12 was insensitive to meaningful changes in prolapse symptoms in this population. 37 
Decision-makers therefore must interpret the results based on a careful reading of the symptoms women suffered and 38 
the extent to which these were relieved. The lack of other economic studies in this field makes it difficult to compare 39 
results, and we look forward to future studies that provide comparisons for these results. 40 
 41 
There are six other randomised studies published to date comparing PFMT with a control.12,30–34 Three of these are 42 
pilot trials making it problematic to draw conclusions from their findings due to their developmental nature and small 43 
sample sizes.12,30,31 Three other full-sized trials have been published.32–34 The Piya-Anant trial32 had methodological 44 
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limitations and high risk of bias and cannot reliably contribute to the evidence-base. No information was provided on 3 
the processes of random sequence generation or allocation concealment; there was no reporting of attrition, selective 4 
reporting of only a subgroup of the women randomised, and uncertainty as to whether the analysis was an intention to 5 
treat analysis.  6 
 7 
Of the remaining two trials, the Brækken single-centre trial33 of PFMT versus control randomised 109 women with 8 
stage I to III prolapse, of which a subgroup of only 69 women were symptomatic and hence comparable to our 9 
population. The very intensive PFMT regimen consisted of weekly appointments for 3 months, followed by bi-weekly 10 
appointments for 3 months: a model of treatment that it would not be possible to deliver in the UK and many other 11 
countries. Kashyap34 recently reported on a single-centre trial in women with stage I to III prolapse which compared 12 
taught PFMT plus a self instruction manual (n=70) with the self instruction manual alone as control (n=70). A single 13 
person delivered the PFMT intervention to all women. The content of the manual was not described and therefore it is 14 
unclear what written instruction the control group received. More importantly, four women transferred from the 15 
control group to the PFMT plus manual group and it is not clear in which group these women were analysed: until this 16 
is clarified the results have limited utility. 17 
 18 
Symptom benefit from PFMT was reported by both Braekken33 and Kashyap34. Braekken analysed women with 19 
symptoms at baseline, and found that those who had received PFMT compared to controls were more likely to have 20 
reduced frequency of symptoms (74% versus 31%) and reduced bother (67% versus 42%). Kashyap reported a 21 
significantly greater mean reduction in POP-SS score post-intervention for the PFMT plus manual group compared to 22 
the control group (2.99 versus 1.25). Neither trial sought evidence about longer term outcomes or effect on the uptake 23 
of other treatments. 24 
  25 
Braekken33 also reported that PFMT improved POP-Q stage: 19% had an improved stage in the intervention group 26 
versus 8% in the control group (11% risk difference). Our finding for POP-Q was marginally non-significant but of a 27 
similar size (risk difference 7.5%, 95% CI [-1.4%, 16.4%]). The most likely reason for the non-significant finding in 28 
our trial is that the study was not powered to show a difference for this outcome. Data on change in the POP-Q or 29 
prolapse stage in the Kashyap trial were not adequately reported to allow comparison.34  30 
 31 
We chose our primary outcome measure to be symptom change: this is usually the driver for seeking treatment for 32 
prolapse, and hence the most important outcome for women. It is increasingly recognised that there is little correlation 33 
between ‘stage’ of prolapse and the prolapse symptoms ascribed to it.35,36 Therefore it is not surprising that, as we 34 
found, an improvement in symptoms does not necessarily correspond to an improvement in stage.  35 
 36 
We found that 45% of women in the control group reported that their prolapse was better at 12 months. This is in part 37 
due to the fact that around half (49%) of these women had received further treatment for prolapse by this time-point. 38 
Although significantly more women in the intervention group compared to the control group reported their prolapse 39 
was better (57% versus 45%), the remaining 43% reported no change or worse prolapse. Thus we conclude that a 40 
substantial group of women did not benefit. One potential reason is that a more intensive intervention might be 41 
required for some women. Another is that some types or stages of prolapse do not respond to PFMT as well as others 42 
and hence better selection of women for PFMT might be required. Although our subgroup analyses (for prolapse stage 43 
13 
 
and type, age and motivation for surgery) did not support these hypotheses, the analyses were exploratory and under-3 
powered to draw firm conclusions. 4 
 5 
It is recognised that prolapse can regress with time, and this could partially explain the improvement we observed. 6 
Three studies of the epidemiology of prolapse have concluded that prolapse can both progress and regress.37–39 The 7 
studies by Handa37 and Bradley38 looked at change in severity of prolapse, but in populations older than our own. The 8 
study by Miedel39 is most relevant for comparison as it examined both symptoms and stage of prolapse over time in 9 
women with a mean age of 56. They found that 44% of stage I prolapses had regressed (improved) to stage 0, 24% of 10 
stage II showed regression, and 64% (95% CI [56%, 72%]) of women had a reduction in symptoms by 5 years. 11 
However the study population was mainly non-consulting women identified by a positive questionnaire response to “a 12 
feeling of a vaginal bulge”, rather than women who were actively seeking treatment for prolapse. As the authors 13 
pointed out, results cannot automatically be generalised to patients who present to health care. Thus we do not know 14 
to what extent women in our trial naturally improved. However, we would expect that any natural regression or 15 
progression would occur equally in both groups by virtue of the group allocation, and hence the observed significant 16 
differences between the groups must be due to the intervention. 17 
 18 
Our trial constitutes the largest, rigorous, pragmatic multicentre trial of PFMT for prolapse, with the longest follow-19 
up, and as such provides the necessary evidence to support changes in clinical practice. However the resource 20 
implications of implementing these findings need to be considered. The physiotherapists delivering the trial 21 
intervention were specialists in women’s health; their numbers are limited and workload is large, currently consisting 22 
mainly of the management of urinary incontinence. With the establishment of an evidence-base for PFMT in the 23 
management of prolapse, healthcare providers will need to invest in extra resources to ensure that a similar service can 24 
be provided for women with prolapse. In addition, outwith the clinical arena, the role of pelvic floor muscle exercises 25 
in alleviating prolapse symptoms is an important public health message, which needs to be shared widely with females 26 
of all ages. 27 
 28 
In summary, we found individualised PFMT was effective, leading to greater reduction in prolapse symptoms in the 29 
PFMT group. The net cost of the intervention was £131.61 per woman, and under plausible conditions this would 30 
prove cost-effective. 31 
 32 
We conclude that PFMT should be recommended for the conservative management of prolapse. Effectiveness of 33 
PFMT in the long-term, in women who have had previous prolapse surgery, in conjunction with pessary use and 34 
within populations of women with different types or combinations of prolapse should be investigated further. 35 Word	  count	  5624 36 
 37 
Research in context (box) 38 
Systematic review 39 
The Cochrane review on the topic of conservative management of prolapse was updated in 2011 by two of the 40 
authors, prior to the completion of the analysis of the current trial. Four trials compared PFMT with a control,12,30,32,33 41 
but two were at significant risk of bias;30,32 of the remaining two, one was the pilot study preceding the current trial.12 42 
Prolapse symptoms were measured differently in the three trials where this was reported,12,30,33 however all three 43 
14 
 
found greater improvement in symptoms in the PFMT group. Limited data from the two trials with low risk of bias12,33 3 
suggested that PFMT increases the chance of an improvement in prolapse stage compared to no PFMT. 4 
Interpretation 5 
Our trial represents the largest, rigorous, pragmatic trial of PFMT versus control for prolapse, and as such provides 6 
important robust evidence to inform clinical practice. Its findings confirm the findings of other smaller or less rigorous 7 
studies that PFMT is beneficial in terms of reducing women’s prolapse symptoms. The findings have implications for 8 
a range of healthcare professionals who care for women with prolapse (general practitioners, gynaecologists, 9 
physiotherapists, nurses, healthcare managers) and for women themselves. 10 
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Table 1. Baseline characteristics 3 
 Intervention (N=225)  Control (N=222)  
Age (mean [SD]), n 56.20 [11.60], 225 57.50 [11.39], 222 
BMI (mean [SD]), n 27.15 [4.99], 214 27.42 [4.57], 210 
Parity (median [IQR]), n 2 [2-3], 223 2 [2-3], 217 
   
Stage of prolapse# (freq [%]):    
Stage I 23/225 (10.2) 18/222 (8.1) 
Stage II (above the hymen) 48/225 (21.3) 47/222 (21.2) 
Stage II (at or below the hymen) 116/225 (51.6) 127/222 (57.2) 
Stage III 38/225 (16.9) 29/222 (13.1) 
Stage IV 0/225 (0.0) 1/222 (0.4) 
   
Type of prolapse (freq [%]):   
Anterior  23/225 (10.2) 25/220 (11.4) 
Posterior 13/225 (5.8) 11/220 (5.0) 
Anterior + posterior 54/225 (24.0) 54/220 (24.5) 
Anterior + upper 27/225 (12.0) 22/220 (10.0) 
Posterior + upper 6/225 (2.7) 8/220 (3.6) 
Anterior + posterior + upper 102/225 (45.3) 100/220 (45.5) 
   
Duration of prolapse symptoms in months (median [IQR], n) 12 [6-24], 196 12 [6-24], 201 
Baseline POP-SS score (mean [SD]), n 10.04 [6.0], 224 9.51 [5.64], 222 
   
Symptom reported in last 4 weeks (n/N [%]):   
Something coming down 193/219 (88.1) 195/219 (89.0) 
Discomfort worse when standing 140/221 (63.3) 147/220 (66.8) 
Abdominal pain when standing 153/222 (68.9) 145/217 (66.8) 
Lower back heaviness 131/222 (59.0) 125/216 (57.9) 
Strain to empty bladder 138/221 (62.4) 109/218 (50.0) 
Feel bladder not empty 159/221 (71.9) 152/218 (69.7) 
Feel bowel not empty 154/221 (69.7) 140/222 (63.1) 
   
Faecal urgency* 138/223 (61.9) 135/221 (61.1) 
Faecal incontinence* 60/223 (26.9) 55/222 (24.8) 
   
Urinary incontinence  145/225 (64.4) 156/221 (70.6) 
Urinary incontinence score (ICIQ UI SF+) (median [IQR]), n 4 [0-7], 218 4 [0-7], 216 
# POP-Q stage reported here was calculated at the analysis stage using a specially developed programme using the 9 individual 4 
POP-Q measurements recorded by the gynaecologist. On occasion this differed from the stage assigned by the gynaecologist which 5 
determined women’s trial eligibility.  6 
+ ICIQ UI SF score: 0=no incontinence, no interference with everyday life; 21=maximum leakage and interference 7 
* faecal urgency = sudden, irresistible need to have a bowel movement; faecal incontinence = any involuntary loss of faecal material 8 
 9 
10 
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Table 2. Intervention group women’s attendance at physiotherapy appointments 3 
No. of appointments attended (%) Frequency (%) 
N=222* 
0 10/222 (4.5%) 
1 9/222 (4%) 
2 10/222 (4.5%) 
3 15/222 (7%) 
4  22/222 (10%) 
5 156/222 (70%) 
* missing data for 3 women from the intervention group 4 
 5 
